Editorial Material
Hematology
Elias Jabbour, Hagop Kantarjian
Summary: Brivio et al demonstrate in their study that inotuzumab ozogamicin is safe and effective for pediatric relapsed-refractory ALL, with a recommended dose of 1.8 mg/m(2.1).
Article
Oncology
Nicola Stefano Fracchiolla, Mariarita Sciume, Cristina Papayannidis, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio, Prassede Salutari, Fabio Forghieri, Davide Lazzarotto, Monia Lunghi, Annalisa Imovilli, Barbara Scappini, Massimiliano Bonifacio, Michelina Dargenio, Carmela Gurrieri, Elisabetta Todisco, Marzia Defina, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Cerrano, Lidia Santoro, Elena Tagliaferri, Enrico Barozzi, Pasquale De Roberto, Marta Canzi, Elisa Buzzatti, Chiara Sartor, Francesco Passamonti, Robin Foa, Antonio Curti, Thomas Wirth
Summary: This retrospective study evaluated the efficacy and safety of blinatumomab and inotuzumab ozogamicin in the treatment of relapsed B-lymphoblastic leukemia. The study demonstrated the feasibility and effectiveness of sequential immunotherapy using these two drugs in terms of minimal residual disease, overall survival, and disease-free survival.
Review
Immunology
Jeremy D. D. Rubinstein, Maureen M. M. O'Brien
Summary: InO is an antibody drug conjugate used to treat relapsed and refractory B-cell precursor acute lymphoblastic leukemia. It has shown significant activity in both adult and pediatric trials. However, there are notable toxicities including sinusoidal obstruction syndrome and myelosuppression. In the relapsed/refractory setting, the subsequent curative therapy modality must be considered to mitigate these risks.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Hematology
David Kegyes, Ciprian Jitaru, Gabriel Ghiaur, Stefan Ciurea, Dieter Hoelzer, Ciprian Tomuleasa, Robert Peter Gale
Summary: About half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve complete remission or relapse are not cured by current therapies. Immune therapies, including monoclonal antibodies, BiTEs, ADCs, and CARs, have shown effectiveness in this setting. This manuscript summarizes FDA-approved immune therapies for advanced adult B-ALL, their efficacy, safety, QoL, and future directions.
Article
Medicine, General & Internal
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Chaoling Feng, Jinghui Dong, Tong Shen, Francesca Milletti, John M. Rossi, Remus Vezan, Behzad Kharabi Masouleh, Roch Houot
Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.
Article
Hematology
Daniel Fischer, Rosa Toenges, Kati Kiil, Sabine Michalik, Axel Thalhammer, Gesine Bug, Nicola Goekbuget, Fabian Lang
Summary: The case of a 58-year-old female patient who experienced a relapse of extramedullary B-ALL after prior allogenic HSCT and blinatumomab therapy is presented. The patient died from complications of drug-induced acute liver failure. The combination therapy of inotuzumab ozogamicin (InO), high-dose MTX, and pegaspargase in a heavily pretreated patient with relapse after HSCT may increase the risk of liver-related toxicity. Caution is needed when assessing fitness for further liver toxic regimens. It is also important to note that InO can cause liver damage through direct hepatocellular toxicity, not just VOD.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Erica Brivio, Christophe F. Chantrain, Tanja A. Gruber, Adriana Thano, Fanny Rialland, Audrey Contet, Sarah Elitzur, Luciano Dalla-Pozza, Krisztian Miklos Kallay, Chi-kong Li, Motohiro Kato, Inna Markova, Kjeld Schmiegelow, Nicole Bodmer, Erin H. Breese, Raoull Hoogendijk, Rob Pieters, Christian Michel Zwaan
Summary: This study collected data on infants and young children under 3 years old with ALL who were treated with InO, showing a 47% complete remission rate and a 6-month overall survival rate of 47%. However, two patients experienced veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL patients is warranted.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Goekbuget, Anjali S. Advani, Susan O'Brien, Michaela Liedtke, Akil A. Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David Marks, Hagop M. Kantarjian
Summary: The study demonstrated that InO was more effective than standard intensive chemotherapy for patients with R/R Ph+ ALL, showing higher rates of complete remission and minimal residual disease negativity, as well as improved hematopoietic stem cell transplantation rates. However, there was no significant benefit in overall survival, and the probability of being event-free at 12 months was higher with InO treatment.
Article
Oncology
Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M. Shallis, Ilana R. Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Balasubramanian, Jay Yang, Mehrdad Hefazi, Nikolai Podoltsev, Anand Patel, Emily Curran, Amy Wang, Shukaib Arslan, Ibrahim Aldoss, Caitlin Siebenaller, Ryan J. Mattison, Mark R. Litzow, Martha Wadleigh, Anjali S. Advani, Ehab Atallah
Summary: A study comparing the efficacy of blinatumomab and InO as first or second NA therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia found that the two agents may have comparable efficacy in this setting.
Article
Oncology
Matthias Stelljes, Anjali S. Advani, Daniel J. DeAngelo, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop Kantarjian, Elias Jabbour
Summary: Retrospective analysis found that patients with relapsed/refractory acute lymphoblastic leukemia who received inotuzumab ozogamicin were less likely to receive additional treatment and had an extended period before needing additional treatment compared to patients who received chemotherapy.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Oncology
Madeleine A. Ochs, Bernard L. Marini, Lydia L. Benitez, Sarah E. Stump, Taylor M. Weis, Kaitlyn M. Buhlinger, Thomas Diaz, Justin H. Reid, Benyam Muluneh, Kristen Pettit, Patrick Burke, Dale L. Bixby, Anthony J. Perissinotti
Summary: There is no significant difference in overall survival and complete remission/complete remission with incomplete count recovery rates between chemotherapy and novel agents as first salvage therapy for relapsed/refractory acute lymphoblastic leukemia. Age is a significant factor influencing the probability of achieving complete remission/complete remission with incomplete count recovery with novel therapy versus chemotherapy.
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
Zahava Ohana, Samantha Serraes, Christopher Elder, Nikolina Katusa
Summary: This article describes a case of a relapse/refractory B-cell ALL patient who failed blinatumomab therapy but achieved a complete response after switching to inotuzumab ozogamicin treatment. There is currently limited clinical guidance on the preferred treatment for adult R/R B-cell ALL, highlighting the need for further research and comparative studies.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Oncology
Anjali S. Advani, Anna Moseley, Kristen M. O'Dwyer, Brent L. Wood, Min Fang, Matthew J. Wieduwilt, Ibrahim Aldoss, Jae H. Park, Rebecca B. Klisovic, Maria R. Baer, Wendy Stock, Rupali R. Bhave, Megan Othus, Richard C. Harvey, Cheryl L. Willman, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Summary: The study evaluated the efficacy of Blinatumomab as induction and consolidation therapy in older patients with Philadelphia chromosome-negative B-acute lymphoblastic leukemia. Results showed Blinatumomab had good tolerability and effectiveness in treatment, with some patients achieving complete remission, and encouraging 3-year disease-free survival and overall survival rates.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Eulalia Genesca, Celia Gonzalez-Gil
Summary: Thanks to high-resolution genetic techniques, we now have a clearer understanding of the genetic landscape in T-ALL and have begun to understand relapse-specific mechanisms. This review summarizes the latest advances in our knowledge of the genome in T-ALL and highlights the areas where research in this ALL subtype is progressing.
Review
Hematology
Ibrahim Aldoss, Bijal D. Shah, Jae H. Park, Lori Muffly, Aaron C. Logan, Patrick Brown, Wendy Stock, Elias J. Jabbour
Summary: The recent approval of four CD19- or CD22-targeted therapies has revolutionized the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). While all options are available for adults with relapsed/refractory B-ALL, there is currently no direct comparison between these agents, leaving the treating physician to make the choice. Each therapy has its own effectiveness as a single agent, though limitations exist for specific situations, and the optimal choice varies. These therapies can be used in combination or sequentially, providing complementary treatment options.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Shilpa Paul, Hagop Kantarjian, Koji Sasaki, Kayleigh Marx, Nitin Jain, J. Michael Savoy, Adam DiPippo, Nadya Jammal, Guillermo Montalban Bravo, Tapan Kadia, Guillermo Garcia-Manero, Nicholas J. Short, Farhad Ravandi, Elias Jabbour
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Hussein A. Abbas, Hanxiao Sun, Sherry Pierce, Rashmi Kanagal-Shamanna, Ziyi Li, Musa Yilmaz, Gautam Borthakur, Adam J. DiPippo, Elias Jabbour, Marina Konopleva, Nicholas J. Short, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan M. Kadia
Article
Hematology
Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero
Summary: The combination of enasidenib with azacitidine showed a 74% overall response rate in newly diagnosed mIDH2 MDS patients, while enasidenib monotherapy achieved a 35% response rate in patients after HMA failure. These findings demonstrate that enasidenib is an effective treatment option for mIDH2 MDS.
Article
Hematology
Aram Bidikian, Elias Jabbour, Ghayas C. C. Issa, Nicholas J. J. Short, Koji Sasaki, Hagop Kantarjian
Summary: Achieving major molecular response (MMR) with BCR::ABL1 tyrosine kinase inhibitors (TKIs) is important in the treatment of chronic myeloid leukemia (CML). However, patients who achieve a major cytogenetic response (MCyR) within the first 2 years of TKI therapy can still have good long-term outcomes, even without achieving MMR. The value of MMR is less pronounced among older CML patients, who often face mortality due to comorbidities unrelated to CML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fadi G. Haddad, Issa Khouri, Courtney D. DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias Jabbour
Summary: The combination of ponatinib and hyper-CVAD chemotherapy showed high rates of complete molecular remissions and survival in patients with Philadelphia chromosome-positive acute lymphocytic leukemia. Further studies with a larger cohort and longer follow-up are needed to establish this regimen as a new standard of care.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Summary: The FDA has an accelerated approval program for potentially promising drugs in treating serious conditions. All available treatments for chronic myeloid leukemia (CML) have undergone this program. A group consisting of CML experts, patient panelists, and FDA members gathered to discuss the utility of the accelerated approval program in CML and its future role in drug development, and the results are summarized here.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Sophie Ifrah, Timothy P. Hughes
Summary: Asciminib, a BCR-ABL1 inhibitor that works through the STAMP mechanism, has shown favorable efficacy and safety in patients with chronic myeloid leukemia in chronic phase. The ongoing ASC4FIRST trial aims to compare the effectiveness of Asciminib with investigator-selected TKIs in newly diagnosed patients with chronic myeloid leukemia.
Article
Oncology
Andreas Hochhaus, Delphine Rea, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin Garcia-Gutierrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Veronique Bedoucha, Michael J. Mauro
Summary: Asciminib, a BCR-ABL1 inhibitor that targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with at least 2 tyrosine kinase inhibitors (TKIs). In the ASCEMBL study, asciminib demonstrated superior efficacy and better safety and tolerability compared to bosutinib in patients with CML-CP who had received at least 2 prior TKIs. The major molecular response rate at week 96 was significantly higher with asciminib than with bosutinib, and fewer adverse events and treatment discontinuations were observed with asciminib.
Article
Hematology
Nicholas J. Short, Elias Jabbour, Walid Macaron, Farhad Ravandi, Nitin Jain, Rashmi Kanagal-Shamanna, Keyur P. Patel, Sanam Loghavi, Fadi G. Haddad, Musa Yilmaz, Ghayas C. Issa, Partow Kebriaei, Steven M. Kornblau, Sarah Pelletier, Wilmer Flores, Jairo Matthews, Rebecca Garris, Hagop Kantarjian
Summary: Reverse transcription polymerase chain reaction (RT-PCR) is commonly used for measurable residual disease (MRD) assessment in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), but it may not be optimal for all cases. A highly sensitive next-generation sequencing (NGS) MRD assay was evaluated and showed a discordance with RT-PCR in 32% of patients with Ph+ ALL. Patients with long-term detectable BCR::ABL1 by PCR had stable levels and did not relapse, while patients who were PCR+/NGS+ had variable PCR values that responded to therapeutic intervention. NGS-based assessment of MRD is prognostic in Ph+ ALL and identifies patients with low-level detectable BCR::ABL1 who are unlikely to relapse nor to benefit from therapeutic interventions.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan, Naval G. Daver, Courtney D. DiNardo, Elias J. Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Y. Konopleva, Michael Andreeff, Farhad Ravandi-Kashani, Koji Sasaki, Ghayas C. Issa
Summary: This retrospective analysis shows that patients with KMT2Ar AML have a higher 60-day mortality rate compared to those with normal karyotype AML, and they are at a higher risk of major bleeding events and total bleeding events. KMT2Ar and monocytic phenotype are independent predictors of bleeding events in patients who died within 60 days.
Article
Oncology
Georgina Gener-Ricos, Fadi G. Haddad, Koji Sasaki, Ghayas C. Issa, Jeffrey Skinner, Lucia Masarova, Gautam Borthakur, Yesid Alvarado, Guillermo Garcia-Manero, Elias Jabbour, Hagop Kantarjian
Summary: Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP, with a 95% incidence of major molecular responses and an 82% incidence of deep molecular responses at 5 years. The 5-year overall survival rate is 96%.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Letter
Oncology
Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. Dinardo
BLOOD CANCER JOURNAL
(2023)
Meeting Abstract
Oncology
Ana Toreli, Marisol Miranda-Galvis, Marcelo Addas-Carvalho, Eliana Miranda, Leonardo Fechio, Adriana Duarte, Audrey Basso, Gislaine Duarte, Samuel Medina, Fernando Pericole, Bruno Benites, Ravindra Kolhe, Kimya Jones, Harmanpreet Singh, Sara Teresinha Olalla Saad, Carmino Antonio de Souza, Jorge Cortes, Katia Pagnano
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Mark J. Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C. N. Chang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)